SpyGlass Pharma (SGP) said late Monday it closed its initial public offering of roughly 10.8 million shares, including the full exercise of an over-allotment option, at $16 apiece, raising $172.5 million in gross proceeds.
The shares began trading on Nasdaq last Friday.